Google
NERV — MINERVA NEUROSCIENCES INC (Healthcare >> Biotechnology)
NERV FAQ
What is NERV's ROE?
MINERVA NEUROSCIENCES INC reports a Return on Equity (ROE) of 163.41%.
What is NERV's dividend yield?
MINERVA NEUROSCIENCES INC offers a dividend yield of 0.00%.
What is NERV's Deepscope Quality Score?
Deepscope rates NERV's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NERV?
Deepscope's AI Timing Score for NERV is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NERV belong to?
MINERVA NEUROSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.78
Price
0.10
(2.14%)
Day Change
|
|
|---|
NERV, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.78 |
| PBV / Sector |
-0.86 / 4.58
|
| Earning Per Share | -9.10 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
0.72 M
GREAT
|
| Average 1W Daily Value |
0.49 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:54 |
| Symbol | NERV |
| Name | MINERVA NEUROSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 46.59 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 218.04 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 District Avenue, Burlington, MA, United States, 01803
Phone: 617 600 7373
Website: https://www.minervaneurosciences.com
Sector: Healthcare >> Biotechnology
Description: Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
